Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2023, at 8:30 a.m. ET to discuss the first quarter financial results and provide a corporate update. The call can be accessed via toll-free numbers for North America and international callers, and a replay will be available for one week post-event. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing anti-cancer immune responses. The company is exploring combinations of pelareorep with checkpoint inhibitors and other oncology treatments, particularly targeting metastatic breast cancer and pancreatic cancer. For further details, visit Oncolytics Biotech's website.
- Oncolytics is advancing pelareorep towards registration studies in metastatic breast and pancreatic cancers.
- Pelareorep shows promise in inducing anti-cancer immune responses and is synergistic with checkpoint inhibitors.
- None.
Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET
SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023.
Conference Call & Webcast
Date: Friday, May 5, 2023
Time: 8:30 a.m. ET
Dial In – North American Toll-Free: (888) 664-6383
Dial In – International: (416) 764-8650
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 3550-3191
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 503-191#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
Company Contact Jon Patton Director of IR & Communication +1-858-886-7813 | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 |
Logo: https://mma.prnewswire.com/media/1808285/3981527/Oncolytics_Biotech_Grey.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-301795286.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What is the date of Oncolytics Biotech's first quarter financial results conference call?
What time will the Oncolytics Biotech conference call start?
How can I access the Oncolytics Biotech conference call and webcast?
What is pelareorep and what is its significance for Oncolytics Biotech?
In which cancers is Oncolytics Biotech planning to conduct clinical trials with pelareorep?
